Newport Beach aesthetics company Evolus Inc. today announced that it’s beginning commercial launch of Nuceiva in France.
The European Commission approved the product, which is licensed as Juveau in the U.S., for temporary improvement in deep frown lines between the eyebrows.
“We entered a key region that advances our global growth strategy and reinforces our dedication to international customers,” Evolus Chief Executive and President David Moatazedi said in a statement.
Evolus is partnering with French private company Symatese to launch Nuceiva. In 2023, Evolus first announced its partnership with Symatese to create a line of five dermal fillers with launches planned for 2026 and 2027.
Shares in Evolus rose 6% to $9.81 and a $632.5 million market cap on news of the announcement (Nasdaq: EOLS).